Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxervate for Neuropathic Corneal Pain
NCT05700864Phase 1Withdrawn
- Sponsor
- Tufts Medical Center
- Start
- Nov 2022
- Primary completion
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cenegermin in neuropathic corneal pain (NCP), sponsored by Tufts Medical Center. Primary endpoints: Efficacy of OXERVATE on neuropathic corneal pain as assessed by corneal nerve regeneration, Changes in ocular inflammation on in vivo confocal microscopy and 1 more. Planned start Nov 2022; status: withdrawn.
02
Drugs
cenegermin
03
Conditions
neuropathic corneal pain (NCP)
Beyond the preview
Go deeper on NCT05700864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05700864.